Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 2
2019 4
2021 2
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

9 results
Results by year
Filters applied: . Clear all
Page 1
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.
Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, Pereira EFR, Albuquerque EX, Thomas CJ, Zarate CA Jr, Gould TD. Zanos P, et al. Among authors: highland jn. Pharmacol Rev. 2018 Jul;70(3):621-660. doi: 10.1124/pr.117.015198. Pharmacol Rev. 2018. PMID: 29945898 Free PMC article. Review.
Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications.
Highland JN, Zanos P, Riggs LM, Georgiou P, Clark SM, Morris PJ, Moaddel R, Thomas CJ, Zarate CA Jr, Pereira EFR, Gould TD. Highland JN, et al. Pharmacol Rev. 2021 Apr;73(2):763-791. doi: 10.1124/pharmrev.120.000149. Pharmacol Rev. 2021. PMID: 33674359 Free PMC article. Review.
(2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions.
Zanos P, Highland JN, Stewart BW, Georgiou P, Jenne CE, Lovett J, Morris PJ, Thomas CJ, Moaddel R, Zarate CA Jr, Gould TD. Zanos P, et al. Among authors: highland jn. Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6441-6450. doi: 10.1073/pnas.1819540116. Epub 2019 Mar 13. Proc Natl Acad Sci U S A. 2019. PMID: 30867285 Free PMC article.
(R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses.
Zanos P, Highland JN, Liu X, Troppoli TA, Georgiou P, Lovett J, Morris PJ, Stewart BW, Thomas CJ, Thompson SM, Moaddel R, Gould TD. Zanos P, et al. Among authors: highland jn. Br J Pharmacol. 2019 Jul;176(14):2573-2592. doi: 10.1111/bph.14683. Epub 2019 May 13. Br J Pharmacol. 2019. PMID: 30941749 Free PMC article.
A Negative Allosteric Modulator for α5 Subunit-Containing GABA Receptors Exerts a Rapid and Persistent Antidepressant-Like Action without the Side Effects of the NMDA Receptor Antagonist Ketamine in Mice.
Zanos P, Nelson ME, Highland JN, Krimmel SR, Georgiou P, Gould TD, Thompson SM. Zanos P, et al. Among authors: highland jn. eNeuro. 2017 Mar 7;4(1):ENEURO.0285-16.2017. doi: 10.1523/ENEURO.0285-16.2017. eCollection 2017 Jan-Feb. eNeuro. 2017. PMID: 28275719 Free PMC article.